Brentuximab vedotin

Generic Name
Brentuximab vedotin
Brand Names
Adcetris
Drug Type
Biotech
Chemical Formula
-
CAS Number
914088-09-8
Unique Ingredient Identifier
7XL5ISS668
Background

Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug labe...

Indication

Brentuximab vedotin is indicated in adult patients for the treatment of previously untreated stage III or IV classical Hodgkin's lymphoma (cHL) in combination with doxorubicin, vinblastine, and dacarbazine. It is also indicated for the treatment of cHL post-autologous hematopoietic stem cell transplantation (auto-HSCT) in patients at high risk of relapse or ...

Associated Conditions
CD30-expressing Mycosis Fungoides (MF), Classical Hodgkin's Lymphoma, Peripheral T-Cell Lymphoma (PTCL), Primary Cutaneous Anaplastic Large Cell Lymphoma, Systemic Anaplastic Large Cell Lymphoma, Stage 3 Classical Hodgkin's Lymphoma
Associated Therapies
-
Clinical Trials
Related News

BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in R/R HL Patients Non Responding to IGEV

First Posted Date
2014-09-18
Last Posted Date
2018-02-09
Lead Sponsor
Fondazione Italiana Linfomi - ETS
Target Recruit Count
13
Registration Number
NCT02244021
Locations
🇮🇹

Ematologia, IRCCS AOU San Martino-IST, Genova, Italy

🇮🇹

SC Ematologia - Azienda Ospedaliera AO Città della Salute e della Scienza, Torino, Italy

🇮🇹

Istituto di Ematologia "L. & A. Seragnoli" , Policlinico S. Orsola Malpighi, Bologna, Italy

and more 4 locations

Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

First Posted Date
2014-08-28
Last Posted Date
2024-02-15
Lead Sponsor
University of Washington
Target Recruit Count
45
Registration Number
NCT02227199
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Brentuximab Vedotin in the Elderly Hodgkin Lymphoma Patients at First Relapse or With Primary Refractory Disease.

Phase 2
Completed
Conditions
Hodgkin Lymphoma
Interventions
Drug: Brentuximab Vedotin
First Posted Date
2014-08-28
Last Posted Date
2020-12-22
Lead Sponsor
Fondazione Italiana Linfomi - ETS
Target Recruit Count
20
Registration Number
NCT02227433
Locations
🇮🇹

ASST Spedali Civili di Brescia, Brescia, BS, Italy

🇮🇹

Policlinico S.Orsola Malpighi, Bologna, Italy

🇮🇹

Irccs Centro Di Riferimento Oncologico Di Aviano (Pn), Aviano, Italia, Italy

and more 3 locations

Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma

Phase 2
Completed
Conditions
Hodgkin Lymphoma
Interventions
Drug: B-CAP
Drug: Brentuximab Vedotin
First Posted Date
2014-07-16
Last Posted Date
2024-08-23
Lead Sponsor
University of Cologne
Target Recruit Count
70
Registration Number
NCT02191930
Locations
🇩🇪

1st Dept. of Medicine, Cologne University Hospital, Cologne, Germany

Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)

Phase 2
Terminated
Conditions
Lymphoma
Interventions
Drug: Brentuximab Vedotin
First Posted Date
2014-06-23
Last Posted Date
2019-11-27
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
2
Registration Number
NCT02169505
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma

First Posted Date
2014-06-18
Last Posted Date
2024-11-13
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
600
Registration Number
NCT02166463
Locations
🇺🇸

Bronson Methodist Hospital, Kalamazoo, Michigan, United States

🇺🇸

Corewell Health Children's, Royal Oak, Michigan, United States

🇺🇸

Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis, Minnesota, United States

and more 196 locations

Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients

First Posted Date
2014-03-28
Last Posted Date
2022-10-27
Lead Sponsor
New York Medical College
Target Recruit Count
20
Registration Number
NCT02098512
Locations
🇺🇸

New York Medical College, Valhalla, New York, United States

Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)

Phase 1
Terminated
Conditions
Leukemia
Interventions
Drug: Brentuximab Vedotin
Drug: 5-Azacytidine
First Posted Date
2014-03-26
Last Posted Date
2023-10-10
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
1
Registration Number
NCT02096042
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma

First Posted Date
2014-03-13
Last Posted Date
2022-02-17
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
37
Registration Number
NCT02086604
Locations
🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

🇺🇸

Ohio State University, James Cancer Hospital, Columbus, Ohio, United States

Brentuximab Vedotin and Chemotherapy in CD30+ PMBL, Diffuse Large B-Cell, and Grey Zone Lymphoma Patients

First Posted Date
2013-11-26
Last Posted Date
2021-01-05
Lead Sponsor
Abramson Cancer Center at Penn Medicine
Target Recruit Count
32
Registration Number
NCT01994850
Locations
🇺🇸

Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy